Thermo Fisher Scientific Inc. (NYSE:TMO)

Current assets exhibited a fluctuating pattern over the five-year period. Initial growth was followed by a decline and subsequent recovery. Reported current assets increased from US$20,113 million in 2021 to US$25,229 million in 2022, representing a substantial rise. A decrease was then observed in 2023, with current assets falling to US$24,589 million. This downward trend continued into 2024, reaching US$22,137 million. However, 2025 saw a significant increase, with current assets rising to US$28,707 million.

Adjusted Current Assets Trend

The trend in adjusted current assets mirrors that of reported current assets. Adjusted current assets increased from US$20,263 million in 2021 to US$25,418 million in 2022. A decline followed in 2023 to US$24,782 million, and continued in 2024 to US$22,310 million. Similar to reported current assets, 2025 showed a marked increase, reaching US$28,854 million.

The difference between reported and adjusted current assets remains relatively consistent across all years. The adjustments made appear to be consistently applied, resulting in a parallel movement of both metrics. The magnitude of the adjustment is approximately US$150 million each year. This suggests a systematic reclassification or valuation adjustment impacting current asset reporting.

Year-over-Year Changes

The largest year-over-year increase in both reported and adjusted current assets occurred between 2021 and 2022. The largest decrease occurred between 2022 and 2024. The most substantial increase occurred between 2024 and 2025.

The recovery in 2025 is notable, indicating a potential shift in working capital management or a change in the composition of current assets. Further investigation into the specific components of current assets would be necessary to understand the drivers behind these fluctuations and the nature of the adjustments made.

Total assets exhibited a generally increasing trend from 2021 to 2025, though with some fluctuation. Reported total assets increased from US$95,123 million in 2021 to US$110,343 million in 2025. However, a slight decrease was observed in 2024, interrupting the overall growth. Adjusted total assets mirrored this pattern, increasing from US$94,265 million in 2021 to US$108,748 million in 2025, also with a dip in 2024.

Overall Growth

Between 2021 and 2025, reported total assets grew by approximately 15.9%, while adjusted total assets increased by approximately 15.4%. This suggests a consistent, moderate expansion of the company’s asset base over the five-year period.

Year-over-Year Changes

From 2021 to 2022, both reported and adjusted total assets increased by roughly 2.1%. A similar increase, approximately 1.6%, was observed from 2022 to 2023. However, 2024 saw a decrease in both metrics; reported total assets declined by approximately 0.8%, and adjusted total assets decreased by approximately 0.7%. The most substantial increase occurred between 2024 and 2025, with reported total assets rising by approximately 13.3% and adjusted total assets increasing by approximately 12.6%.

Difference Between Reported and Adjusted Values

A consistent difference exists between reported and adjusted total assets in each year. The adjustment consistently reduces the reported value, ranging from approximately US$858 million in 2021 to approximately US$1,595 million in 2025. This suggests the presence of items impacting the reported total assets that are being removed in the adjusted figure. The magnitude of this difference increased over the period, indicating a growing impact from these adjustments.

The fluctuations in both reported and adjusted total assets, particularly the decrease in 2024 followed by a substantial increase in 2025, warrant further investigation to understand the underlying drivers. The consistent adjustment to total assets also merits scrutiny to determine the nature of these adjustments and their potential impact on the company’s financial position.

Current liabilities exhibited volatility over the five-year period. Initially increasing significantly, they subsequently decreased before rising again in the final year. Adjusted current liabilities mirrored this pattern, demonstrating a similar trend with minor variations.

Overall Trend

From 2021 to 2022, current liabilities increased by 26.5%, rising from US$13,436 million to US$17,010 million. A subsequent decrease of 17.6% was observed between 2022 and 2023, bringing the value down to US$14,012 million. A further decline of 7.1% occurred from 2023 to 2024, reaching US$13,332 million. Finally, current liabilities increased by 13.6% from 2024 to 2025, concluding at US$15,189 million.

Adjusted Liabilities Comparison

Adjusted current liabilities followed a comparable trajectory. The increase from 2021 to 2022 was 26.3%, moving from US$13,419 million to US$16,969 million. The decrease from 2022 to 2023 was 17.5%, resulting in a value of US$13,952 million. A decrease of 7.2% was noted from 2023 to 2024, reaching US$13,282 million. The final increase from 2024 to 2025 was 13.8%, ending at US$15,119 million.

Difference Between Reported and Adjusted Values

The difference between current liabilities and adjusted current liabilities remained relatively small throughout the period, ranging from US$17 million to US$50 million. This suggests that the adjustments made were not substantial in magnitude. The adjustments appear to be consistently reducing the reported current liability value.

The fluctuations in both current and adjusted liabilities warrant further investigation to understand the underlying drivers. Potential causes could include changes in accounts payable, short-term debt, accrued expenses, or deferred revenue. The consistent nature of the adjustments suggests a systematic accounting practice or correction of classification errors.

Total liabilities exhibited a fluctuating pattern over the five-year period. Initially decreasing from 2021 to 2023, they then declined more substantially in 2024 before increasing significantly in 2025. Adjusted total liabilities mirrored this trend, though the magnitude of change was generally less pronounced.

Overall Trend

From 2021 to 2023, both total and adjusted liabilities demonstrated a gradual decline. Total liabilities decreased from US$54,146 million to US$51,884 million, while adjusted liabilities fell from US$50,292 million to US$49,902 million. This suggests a period of debt reduction or liability management. A more significant decrease occurred in 2024, with total liabilities dropping to US$47,650 million and adjusted liabilities to US$46,332 million. However, 2025 saw a substantial increase in both metrics, with total liabilities rising to US$56,806 million and adjusted liabilities reaching US$55,243 million. This indicates a potential increase in borrowing or the recognition of new liabilities.

Magnitude of Adjustments

The difference between total liabilities and adjusted total liabilities remained relatively consistent throughout the period. In each year, the adjustment reduced the reported liabilities by approximately US$3,000 to US$4,000 million. This suggests a systematic adjustment being applied, potentially related to specific liability classifications or accounting treatments. The consistency of this adjustment implies a recurring nature, rather than a one-time event.

Year-over-Year Changes

The largest year-over-year decrease in total liabilities occurred between 2023 and 2024, with a reduction of US$4,234 million. The most substantial increase occurred between 2024 and 2025, with an increase of US$9,156 million. Similar patterns were observed in adjusted total liabilities. These significant shifts in 2024 and 2025 warrant further investigation to understand the underlying drivers.

The observed fluctuations in total and adjusted liabilities suggest dynamic liability management practices. The substantial increase in 2025 requires further scrutiny to determine its impact on the company’s financial position and future performance.

Total shareholders’ equity exhibited a consistent upward trajectory between December 31, 2021, and December 31, 2025. However, adjusted total equity demonstrates a slightly different pattern, consistently exceeding reported equity and showing a similar, but more pronounced, growth trend.

Shareholders’ Equity Trend

Shareholders’ equity increased from US$40,793 million in 2021 to US$53,407 million in 2025, representing a cumulative growth of approximately 31.1%. The year-over-year increases were US$3,185 million (7.8%) from 2021 to 2022, US$2,757 million (6.3%) from 2022 to 2023, US$2,849 million (6.1%) from 2023 to 2024, and US$3,823 million (7.7%) from 2024 to 2025. The growth rate appears to be accelerating in the later periods.

Adjusted Equity Trend

Adjusted total equity began at US$43,973 million in 2021 and rose to US$53,505 million by 2025, a cumulative increase of approximately 21.6%. Annual increases were US$2,389 million (5.4%) from 2021 to 2022, US$1,386 million (3.2%) from 2022 to 2023, US$1,046 million (2.2%) from 2023 to 2024, and US$98 million (0.2%) from 2024 to 2025. While still positive, the rate of increase in adjusted equity decelerated significantly in the final period.

Relationship Between Reported and Adjusted Equity

The difference between adjusted total equity and total shareholders’ equity was US$3,180 million in 2021. This difference widened to US$3,712 million in 2022, then to US$3,851 million in 2023, and US$4,648 million in 2024. By 2025, the difference reached US$3,798 million. The initial widening suggests that the adjustments made to equity are becoming more substantial over time, although the difference decreased in the final period. This indicates the adjustments are not consistently increasing in magnitude.

The consistent positive adjustments to equity suggest the presence of items not fully reflected in the initially reported shareholders’ equity. Further investigation into the nature of these adjustments would be necessary to understand their impact on the overall financial position and performance.

Over the five-year period ending December 31, 2025, both reported and adjusted financial figures demonstrate generally increasing trends, though with some fluctuations. Total reported debt remained relatively stable between 2021 and 2023, decreased in 2024, and then increased significantly in 2025. Shareholders’ equity exhibited consistent growth throughout the period. Total reported capital followed a similar pattern to equity, increasing steadily until 2025. The adjusted figures show comparable trends, with adjusted debt and equity also increasing over time, and adjusted total capital mirroring the overall capital trend.

Debt Analysis

Total reported debt experienced a slight decrease from US$34,870 million in 2021 to US$34,488 million in 2022, followed by a modest increase to US$34,917 million in 2023. A more substantial decrease was observed in 2024, falling to US$31,275 million, before rising considerably to US$39,385 million in 2025. Adjusted total debt mirrored this pattern, remaining relatively consistent for the first three years, decreasing in 2024, and increasing in 2025 to US$40,855 million.

Equity Analysis

Total Thermo Fisher Scientific Inc. shareholders’ equity increased steadily from US$40,793 million in 2021 to US$53,407 million in 2025. Adjusted total equity also demonstrated consistent growth, moving from US$43,973 million in 2021 to US$53,505 million in 2025. The adjusted equity figures are consistently higher than the reported equity figures throughout the period.

Capital Structure Analysis

Total reported capital increased from US$75,663 million in 2021 to US$92,792 million in 2025, with a slight dip in 2024 to US$80,859 million. Adjusted total capital followed a similar trajectory, rising from US$80,312 million in 2021 to US$94,360 million in 2025, also with a decrease in 2024 to US$83,007 million. The difference between reported and adjusted capital narrowed over the period, with the adjusted figures consistently exceeding the reported figures.

The increases in both reported and adjusted equity and capital suggest overall financial growth. The fluctuations in debt levels, particularly the increase in 2025, warrant further investigation to understand the underlying reasons, such as potential acquisitions, increased financing, or changes in debt structure. The consistent difference between reported and adjusted figures indicates the presence of adjustments being made to the capitalization structure, which may be related to accounting treatments or specific financial instruments.

Net income attributable to Thermo Fisher Scientific Inc. exhibited fluctuations over the five-year period. Initially decreasing from 2021 to 2023, it showed signs of recovery in 2024 and 2025. However, adjusted net income demonstrates a more pronounced and sustained decline, followed by a recovery pattern mirroring, but lagging, the trend in reported net income.

Net Income Trend

Reported net income decreased from US$7,725 million in 2021 to US$5,995 million in 2023, representing a cumulative decline of approximately 22.4%. A subsequent increase to US$6,335 million in 2024 and further to US$6,704 million in 2025 indicates a partial recovery, though net income remained below the 2021 level.

Adjusted Net Income Trend

Adjusted net income experienced a more substantial decrease, falling from US$7,571 million in 2021 to US$4,537 million in 2023, a decline of roughly 40.3%. Similar to reported net income, adjusted net income began to recover in 2024, reaching US$5,612 million, and continued to rise to US$6,325 million in 2025. Despite the recovery, the 2025 value remains below the 2021 figure.

Relationship Between Reported and Adjusted Net Income

The difference between reported and adjusted net income varied over the period. In 2021, the difference was relatively small at US$154 million. This difference widened in 2022 to US$1,708 million and further in 2023 to US$1,458 million. The gap narrowed in 2024 to US$723 million and again in 2025 to US$379 million, suggesting a convergence of reported and adjusted earnings as the period progressed. This indicates that the adjustments made to net income were more significant in the earlier years of the period, and their impact lessened in later years.

The consistent downward trend in adjusted net income from 2021 to 2023, exceeding the decline in reported net income, suggests the presence of significant non-recurring items or accounting adjustments impacting the company’s underlying profitability. The subsequent recovery in both metrics from 2024 onwards implies a stabilization of core earnings and a diminishing effect of these adjustments.